2024-519811-32-00Not yet recruitingPhase 4
An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Feb 2026
Brief summary (registry, in English)
The primary objective of this trial is to confirm the effectiveness of lebrikizumab in improving eczema in patients with moderate-to-severe AD.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 1 Apr 2026
- Lead sponsor
- Region Oestergoetland
- Diseases
- Atopic dermatitis (eczema)
- EU CT number
- 2024-519811-32-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults and adolescents with moderate to severe atopic dermatitis (eczema) who are candidates for systemic therapy and did not respond well enough to creams or ointments.
- Age
- Adults aged 18-64, and adolescents aged ≥12 to <18 years who weigh ≥40 kg.
- Sex
- Men and women can join.
- Disease stage
- Moderate to severe atopic dermatitis (eczema). Candidates for systemic AD therapy.
- Earlier treatment
- A history of inadequate response to topical (skin) treatment, as assessed by the clinician.
Main reasons for not taking part
- Allergy to lebrikizumab or any of its ingredients
- Existing helminth (worm) infection
- Use of live or live attenuated vaccines at the same time
- Pregnant or breastfeeding women
- Cannot understand the study information in Swedish or English
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of live and live attenuated vaccines
Other illness
- Hypersensitivity to the active substances or to any of the excipients of lebrikizumab
- Patients with pre-existing helminth infections
Other
- Pregnant and/or breastfeeding women.
- Patients unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study
- Patients unable to understand the study’s information and conduct in Swedish or English translations of the material
Who the study is looking for
- The participant has given their written consent to participate in the trial.
- Adults (aged 18-64) and adolescents (aged ≥12 to <18 years at the time of ICF/informed assent form (IAF) signature and weighing ≥40 kg) who are candidates for systemic AD therapy.
- Diagnosis of AD and a history of inadequate topical treatment response as assessed by the clinician.
- Adolescent participants (aged ≥12 to <18 years) must have their written informed consent signed by the parent/legal guardian. Adolescent participants from 15 years also need to give their own written consent to participate in the trial.
Age in the registry: - to 64 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Region Dalarna | Falun | Sweden | Not yet recruiting |
| Sahlgrenska University Hospital-Vaestra Goetalandsregionen | Goteborg | Sweden | Not yet recruiting |
| Region Oestergoetland | Linkoping | Sweden | Not yet recruiting |
| Region Skane Skanes Universitetssjukhus | Lund | Sweden | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.